CDMO, CMO, Supplier Roundup in Supporting COVID-19 Projects

By Patricia Van Arnum - DCAT Editorial Director

August 12, 2021

The latest from CDMOs/CMOs and suppliers in COVID-19 projects featuring Seppic and SiO2 Materials Science.

Biologics Manufacturing

Akston, Seppic in Supply Pact for COVID-19 Vaccine Adjuvant
Akston Biosciences, a Beverly, Massachusetts-based bio/pharmaceutical company, has formed a commercial supply agreement with Seppic, a Paris-based supplier of specialty healthcare ingredients, for the supply of adjuvant for Akston’s COVID-19 Fc fusion protein vaccine candidate, AKS-452.

Seppic will provide an adjuvant (Montanide ISA 720 VG) for the vaccine and is working with Akston to produce 10 million doses of adjuvant by late 2021 and up to 100 million doses per month in 2022. Seppic has started the ramp-up of the adjuvant in one of its manufacturing facilities in France. The two companies began collaborating for the development of AKS-452 in the summer of 2020.

AKS-452 is a protein subunit vaccine that is in Phase II testing at the University Medical Center Groningen in the Netherlands.

Source: Akston Biosciences


Packaging

SiO2 Materials Science in $64-M US Gov’t Pact for Vaccine Packaging
SiO2 Materials Science, an advanced materials science company, has entered into a $64-million agreement with the US government to support additional infrastructure of the company's primary packaging containment system platform for storing biological vaccines and therapeutics, including SARS-CoV-2, the virus that causes COVID-19.

The agreement is with the Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense in partnership with the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services.  

SiO2 Materials Science has a 300,000-square-foot manufacturing campus in Auburn, Alabama.

Source: SiO2 Materials Science